Literature DB >> 26272048

Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

S Vincent Rajkumar1, Paul Richardson2, Jesus F San Miguel3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26272048     DOI： 10.1182/blood-2015-05-647636

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Natural history of t(11;14) multiple myeloma.

Authors:  A Lakshman; M Alhaj Moustafa; S V Rajkumar; A Dispenzieri; M A Gertz; F K Buadi; M Q Lacy; D Dingli; A L Fonder; S R Hayman; M A Hobbs; W I Gonsalves; Y L Hwa; P Kapoor; N Leung; R S Go; Y Lin; T V Kourelis; J A Lust; S J Russell; S R Zeldenrust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

2.  Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression.

Authors:  Polona Novak; Evgeny Klyuchnikov; Ute-Marie von Pein; Martina Güllstorf; Maximilian Christopeit; Francis Ayuk; Maria Geffken; Christine Wolschke; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2020-04-29       Impact factor: 5.483

3.  Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Authors:  Li-Wen Huang; Wendi Bacon; Constance Cirrincione; Bercedis Peterson; Gwynn Long; David Rizzieri; Keith M Sullivan; Kelly Corbet; Mitchell Horwitz; Nelson Chao; Cristina Gasparetto; Sascha A Tuchman
Journal:  Hematol Oncol       Date:  2017-01-19       Impact factor: 5.271

4.  Impact of acquired del(17p) in multiple myeloma.

Authors:  Arjun Lakshman; Utkarsh Painuly; S Vincent Rajkumar; Rhett P Ketterling; Prashant Kapoor; Patricia T Greipp; Angela Dispenzieri; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Adv       Date:  2019-07-09

Review 5.  Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

Authors:  Shaji Kumar; Lawrence Baizer; Natalie S Callander; Sergio A Giralt; Jens Hillengass; Boris Freidlin; Antje Hoering; Paul G Richardson; Elena I Schwartz; Anthony Reiman; Suzanne Lentzsch; Philip L McCarthy; Sundar Jagannath; Andrew J Yee; Richard F Little; Noopur S Raje
Journal:  Blood Cancer J       Date:  2022-06-29       Impact factor: 9.812

6.  Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations.

Authors:  Archana M Rajan; Francis K Buadi; Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

7.  Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

Authors:  Shuji Ozaki; Hiroshi Handa; Hiromi Koiso; Takayuki Saitoh; Kazutaka Sunami; Tadao Ishida; Kenshi Suzuki; Tomoko Narita; Shinsuke Iida; Yuichi Nakamura; Kazuhito Suzuki; Noriko Nishimura; Hirokazu Murakami; Kazuyuki Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-02       Impact factor: 4.553

8.  Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status.

Authors:  Christopher E Jensen; Sanah N Vohra; Kirsten A Nyrop; Allison M Deal; Hyman B Muss; Eben I Lichtman; Samuel M Rubinstein; William A Wood; Nicholas J Mangieri; Lee Jamison; Shakira J Grant; Sascha A Tuchman
Journal:  J Geriatr Oncol       Date:  2021-08-11       Impact factor: 3.929

9.  High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Authors:  Yago Nieto; Benigno C Valdez; Sai R Pingali; Roland Bassett; Ruby Delgado; John Nguyen; Nina Shah; Uday Popat; Roy B Jones; Borje S Andersson; Alison Gulbis; Sairah Ahmed; Qaiser Bashir; Simrit Parmar; Krina Patel; Alan Myers; Gabriela Rondon; Robert Z Orlowski; Richard Champlin; Muzaffar Qazilbash
Journal:  Lancet Haematol       Date:  2017-05-15       Impact factor: 18.959

10.  Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.

Authors:  Xiang Zhou; Maximilian J Steinhardt; Denise Grathwohl; Katharina Meckel; Katharina Nickel; Hans-Benno Leicht; Franziska Krummenast; Hermann Einsele; Leo Rasche; Klaus M Kortüm
Journal:  Cancer Med       Date:  2020-07-01       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.